Germany June Composite PMI Flash 50.9, Highest Since February
Pharmaceuticals Biotechnology and Life Sciences
More
-
Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease treatment.
-
BRUSSELS, June 19- Nine drugmakers, including Denmark's Lundbeck, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
-
BRUSSELS, June 19- EU antitrust regulators fined nine drugmakers a total of 146 million euros on Wednesday for blocking the supply of cheaper medicines on the market, with a penalty of 94 million euros imposed on Denmark's Lundbeck.
-
WASHINGTON, June 18- Mississippi's attorney general said on Tuesday he would subpoena documents from Google Inc as part of a probe into allegations the Web search company facilitated the sale of drugs without a prescription and other illegal products.
-
TAKEOVER UPDATE: Royalty Pharma said Tuesday it has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.
-
NEW YORK, June 18- Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation.
-
Some scientists to move to Cambridge before 2016. LONDON, June 18- Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.
-
June 18- The U.S. Food and Drug Administration on Tuesday said it was investigating the deaths of two patients who died following injections with Eli Lilly and Co's long-acting treatment for schizophrenia, called Zyprexa Relprevv.
-
DUBLIN, June 18- U.S.-based Royalty Pharma has dropped a hostile bid worth up to $8 billion for Elan, leaving the Irish drugmaker free to seek other suitors having put itself up for sale last week.
-
A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.
-
NEW YORK-- Shares of drug developer Synergy Pharmaceuticals Inc. traded higher Monday after a Citi Investment Research analyst started covering the stock with a "Buy" rating based on the company's constipation drug candidate plecanatide. THE BIG PICTURE: The New York company has no approved drugs, and plecanatide is its most advanced experimental product.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday regulators can challenge deals between brand-name drug companies and generic rivals that delay cheaper medicines from going on sale, which regulators say increase costs to consumers by billions of dollars.
-
NEW YORK-- BioScrip Inc. plans to expand its drug infusion business with a $223 million acquisition of CarePoint, which administers drugs to patients in their homes and other locations outside of hospitals. BioScrip expects about $160 million in annual revenue from CarePoint, while BioScrip posted $663 million in revenue in 2012..
-
NEW YORK-- Teva Pharmaceutical Industries Ltd. said Monday that it is buying MicroDose Therapeutx for $40 million to build its pipeline of respiratory products. Teva, based in Israel, is one of the world's largest makers of generic drugs. U.S.-traded shares of Teva added 20 cents to $39.28 in Monday afternoon trading.
-
NEW YORK, June 17- ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
-
NEW YORK, June 17- ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.
-
ALLEGAN, Mich.-- Perrigo Co. said Monday that it bought the ophthalmic ointment and solution portfolio of Fera Pharmaceuticals LLC for $93 million in cash. Perrigo has been looking for an ophthalmic deal as part of its strategy to expand its presence in the niche topical medication market.
-
The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals brand-name drug companies make with generic rivals that keep cheaper products off the market.
-
SOUTH SAN FRANCISCO, Calif.-- Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through. South San Francisco, Calif.- based Theravance said Monday it will split into businesses named Royalty Management Co. and Theravance Biopharma.
Most Popular Video
No reason has been given yet for the departure of founder and executive chairman George Zimmer, reports CNBC's Courtney Reagan. Zimmer has long been the face of the company.
Wednesday, 19 Jun 2013 | 10:52 AM ETCNBC's Rick Santelli, explains why he hears 'crickets" when he asks questions about Fed Chairman Bernanke's policies. "Enough is enough," he rants.
Wednesday, 19 Jun 2013 | 11:36 AM ETAre reporters lobbing "softball" questions at the Fed chairman? CNBC's Rick Santelli and the Wall Street Journal's Jon Hilsenrath, debate whether the economy continues to need quantitative easing. I'm trying to inform the public about what the Fed is up to, says Hilsenrath.